

The **Child and Adolescent Psychiatry Department** at the **Hospital General Universitario Gregorio Marañón** and the **Instituto de Investigación Sanitaria Gregorio Marañón** is a leading centre for the research and clinical practice of Child and Adolescent Psychiatry in Madrid, Spain. Our centre offers psychiatric assistance to a catchment area of more than 3.5 million inhabitants (more than 650.000 aged 12-18), through inpatient and outpatient facilities and different specialized clinics, providing an optimal clinical setting for developing clinical research projects. The associated research group is multidisciplinary, reflecting our interest in translational research, and includes professionals from a wide range of disciplines such as psychiatry, biochemistry, biology, neuroimaging, neuropsychology, or genetics among others. We have been developing productive and sustained collaborative research with other research facilities at national and international level.

#### **Scientific interests:**

The main lines of research of the group include early-onset psychosis, autism spectrum disorders, bipolar spectrum disorders, suicide, and offspring of parents with bipolar disorder and schizophrenia and other high-risk populations. Our research interest is focused cross-sectionally on cognition and endophenotypes, neuroimage, genetics, inflammation and oxidative stress mechanisms, developmental neuropsychopharmacology, and psychosocial interventions.

#### **Overview of projects developed so far:**

Research is conceived as multicentric and collaborative with other national and international centres, and public and private funds (7th Framework Programme, NARSAD, NIMH, Stanley Foundation, among others). We are currently involved in 10 European projects financed by the 7th Framework Programme (EU-GEI, PERS, OPTIMISE, STOP, ERANET-NEURON, ROAMER, METSY, PSYSCAN, MATRICS, and AGRESSOTYPE) and in several proposals for HORIZON 2020. We coordinate 2 independent placebo-controlled clinical trials in children and adolescents with autism and psychotic disorders.

#### **Clinical capabilities:**

-Number of patients seen by year: 1500 new referrals

-Availability of patients and volunteer databases: we have access to patient databases and cohorts of patients with early-onset psychosis, autism spectrum disorders, and bipolar disorder. Since 2000, more than 500 patients, from which baseline assessments and biological samples are available, have participated in the early-onset and first-episode psychosis studies of the department, and more than 50 have already completed a 5-year follow-up. Almost 300 trios have participated in our autism genetic studies.

-Easy access to particular patient or volunteer groups through affiliated clinics, consortia: Patient advocacy groups are contacted regularly by our research team for recruitment and dissemination purposes. Thus, informative talks on the research projects take place regularly, and patient associations are contacted for other educational activities of the department, such as courses or presentations. Furthermore, information on every research project is also included in our webpage

and contact data are provided for any patients potentially interested in participating in any research activities (<http://ua.hggm.es>).

-Capability of performing clinical trials: type of patients, ages, possibility of placebo-controlled trials: we have experience with clinical trials (medication and psychosocial interventions), including placebo-controlled trials, in children and adolescents with early-onset psychosis and autism spectrum disorders.

**Technical capabilities:**

-list the technology available at your institution (e.g. neuroimaging): We have access to neuroimaging (MRI facilities of 1.5, 3, and 7 Tesla, spectroscopy, MEG), genetics, clinical assessments, neurocognitive/neuropsychological assessments, biochemistry, and have also developed animal models of psychosis.